http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105663096-B

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7007
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
filingDate 2016-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2019-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2019-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-105663096-B
titleOfInvention A kind of Wo Nuolazan oral quick-dissolving film preparation and preparation method thereof
abstract The invention discloses a kind of Wo Nuolazan oral quick-dissolving film preparations and preparation method thereof, belong to field of pharmaceutical preparations.Specifically, the oral quick-dissolving film preparation includes following component by weight percentage: Wo Nuolazan activated monomer 10-15%;Hydroxypropyl methylcellulose 50-55%;Maltodextrin 25-30%;Hyaluronic acid 0.8-1.0%;Plasticizer 5-10%.Oral quick-dissolving film preparation of the invention passes through preferred water-soluble hydroxypropyl methylcellulose, maltodextrin, hyaluronic acid as filmogen, and screens suitable plasticizer and its weight proportion, and the film of disintegration time and satisfactory mechanical property has been made.Oral quick-dissolving film preparation of the invention can dramatically speed up the disintegration time limited of film, and solving the disadvantage that most of oral solid formulation is taken at present needs water, will not delay medication time in the case where no water resource, improve the medication compliance of patient.
priorityDate 2016-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452430783
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15981397
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23663392
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1110
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474094
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426260389
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483452
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45375887
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24832095
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID753
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450770914
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420041791

Total number of triples: 34.